A Study of a Fully Human BCMA-targeting CAR (CT103A) Combined With Selinexor in Patients With Relapsed/Refractory Extramedullary Multiple Myeloma

NCT05201118 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Extramedullary Multiple Myeloma

Interventions

DRUG: Selinexor
DRUG: CT103A

Sponsor

Chunrui Li

Collaborators

[object Object]